• 1.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306.

  • 2.

    Heerspink HJL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 2019; 393:19371947.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Mann JF, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527535.

  • 4.

    Trachtman H, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29:27452754.

Endothelin Receptor Antagonism in CKD: SONAR and Beyond

  • 1 Donald Kohan, MD, PhD, is DRF Endowed Chair in Nephrology, and professor of medicine at the University of Utah Health Center in Salt Lake City.
Restricted access